Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Presentation (July 2024)
82 slides from Diasorin's investor presentation, Jul 29, 2024
Slide 1: The right test at the right time
The right test at the right time
Slide 2: Disclaimer
Disclaimer In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by DiaSorin S.p.A. (“Diasorin” or the “Co
Slide 3: Healthcare challenges and solutions
Healthcare challenges and solutions
Slide 4: Today, challenges in healthcare are more acute than ever before
Healthcare challenges and solutions Today, challenges in healthcare are Reimbursement more acute challenges than ever before Rising cost Staff shortages DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 4
Slide 5: Massive growth in expenses and rising inflation fuel financial challenges for hospitals
Healthcare challenges and solutions Massive growth in expenses and rising inflation fuel continued financial challenges for America's Hospitals Rising cost and Health Systems* Economy-wide inflation grew by 12.4% Financial reserves for nonprofit hospitals and health between 2021 and 2023 - more than
Slide 6: Respiratory panels coverage is limited
Healthcare challenges and solutions Respiratory Panels coverage is limited to when Reimbursement targeted testing challenges is not appropriate % change in key metrics of hospital profitability relative to 2018 and according 40% to the patient 30% condition 20% 10% 0% 2018 2019 2020 2021 2022 2023 -
Slide 7: Volume of testing and test menus continue to grow
Healthcare challenges and solutions Volume of testing and test menus Staff shortages continue to grow, but the workforce is aging and is retiring at a rate that outpaces annual growth AACC Whitepaper on Overcoming Lab Staffing Shortages | myadlm.org DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O
Slide 8: Laboratories define strategies to face the challenges
Healthcare challenges and solutions Laboratories define strategies Choose tests to face the that are challenges automated, easy, flexible Focus on cost optimization, Optimize reducing for best redundant clinical testing value DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 8
Slide 9: Diagnostic stewardship
Healthcare challenges and solutions Strategies are executed by implementing diagnostic stewardship initiatives Diagnostic stewardship aims to ensure that the correct test is ordered for the right patient at the Increased publication rate, ~800 publications/year1 right time, and to prompt the right a
Slide 10: Diagnostic stewardship interventions that make a difference
Healthcare challenges and solutions Why is it advocated? Practice testing appropriateness for “ Diagnostic the patient’s condition and the pre-test probability of the suspected disease to stewardship prevent unnecessary testing and interventions reduce healthcare costs and make that make a informed
Slide 11: Algorithms are the outcome of diagnostic stewardship initiatives
Healthcare challenges and solutions Algorithms (workflow) are the outcome of diagnostic stewardship initiatives Institutions design algorithms (workflow) that provide best clinical value, optimizing costs and increasing staff efficiencies DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 2
Slide 12: Diasorin's answer to molecular stewardship
Healthcare challenges and solutions Diasorin’s answer to molecular stewardship >10 plex LIAISON MAGPIX® / PLEX® NxTag MULTIPLEXING CAPABILITIES 10 plex 1-6 plex LIAISON® NES* LIAISON® MDX / LIAISON® MDX Plus* 1 2-4 8 - 32 100 *currently in development. Not available for sales PLATFORM THROUGHPUT DIA
Slide 13: Combination of several variables determines the best testing approach
Healthcare challenges and solutions Combination of several variables Winter Summer Spring Autumn determines the best testing approach Pediatrics Elderly Adults Immunocompetent Immunocompromised Seasonality: winter, summer, spring, autumn Central lab Clinics Urgent care Emergency room Patient profi
Slide 14: Current solutions answer the challenges, but there is room for improvement
Healthcare challenges and solutions Current solutions utilize the tools available on the market to answer the challenges in the best possible way… … but there is room for improvement to accomplish the mission in an optimal way DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 1
Slide 15: Optimal diagnostic stewardship
Healthcare challenges and solutions Customization Ease of use, automation Optimal diagnostic Ability to adapt to the stewardship specific case Flexibility DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 15
Slide 16: Molecular market landscape and our strategy
Molecular market landscape and our strategy
Slide 17: Diasorin's answer to molecular stewardship
Molecular market landscape and our strategy Diasorin’s answer to molecular stewardship >10 plex Gastrointestinal MAGPIX® / LIAISON ~$ 380M NxTag PLEX® MULTIPLEXING CAPABILITIES Blood Culture 10 plex ~$ 120M CNS Respiratory ~$ 50M ~$ 2.0B Blood Borne ~$ 880M STI 1-6 plex HPV, CT/NG ~$ 160M HAI ~$ 1.8
Slide 18: LIAISON PLEX
Molecular market landscape and our strategy LIAISON PLEX® DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 18
Slide 19: LIAISON PLEX
Molecular market landscape and our strategy LIAISON PLEX® Touchscreen interface Random Scalable access Room Sample-to- temperature answer workflow storage Flex Testing DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 19
Slide 20: LIAISON PLEX
Molecular market landscape and our strategy LIAISON PLEX® Proven NanoGrid Technology Ambient Storage Fully Integrated Cartridge DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 20
Slide 21: Look at prevalence... Flexibility
Molecular market landscape and our strategy Look at prevalence... Flexibility What could the most probable cause of the disease be? Finding the positive pathogen with minimal ? financial burden DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 21
Slide 22: Look at prevalence... Flexibility
Molecular market landscape and our strategy Look at prevalence... Flexibility What could the most probable cause of the disease be? Finding the positive pathogen with minimal ? financial burden Child Target the subset of most common pathogens found in children DIASO RIN MO LECULAR DIAG NO ST ICS DAY
Slide 23: Look at prevalence... Flexibility
Molecular market landscape and our strategy Look at prevalence... Flexibility What could the most probable cause of the disease be? Finding the positive pathogen with minimal ? financial burden Winter Target the seasonal frequent pathogens DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY,
Slide 24: Look at prevalence... Flexibility
Molecular market landscape and our strategy Look at prevalence... Flexibility What could the most probable cause of the disease be? Finding the positive pathogen with minimal ? financial burden Transplant patient Target all pathogens being similarly prevalent DIASO RIN MO LECULAR DIAG NO ST ICS DAY
Slide 25: PLEX RSP Prospective Clinical Data Analysis
Molecular market landscape and our strategy PLEX RSP Prospective Clinical Data Analysis 30% 27% The probability of infection by respiratory 20% 15% 15% 9% 10% 9% pathogens varies by 10% 6% 8% age 1% 0% 1% 0% 0% 40% 35% Detection rate (%) 10% 30% 25% 20% 14% 8% 6% 21% 10% 3% 4% 3% 0% 0% 1% 0% 0% 40%
Slide 26: Prospective Clinical Data Analysis
Molecular market landscape and our strategy Prospective Young (0 - 21y) Adult (21 - 65y) Elderly (> 65y) Clinical Data HEV/HRV 27.0% SARS - Co V-2 35.0% SARS - Co V-2 40.0% Analysis AdV hM PV 11.1% 15.0% HEV HRV 14.4% Flu A Flu A-H3 16.7% 12.7% Flu A 12.8% There is a common set of HCoV 9.0% HEV HRV
Slide 27: Prospective Clinical Data Analysis
Molecular market landscape and our strategy Prospective Young (0 - 21y) Adult (21 - 65y) Elderly (> 65y) Clinical Data HEV/HRV 27.0% SARS - Co V-2 35.0% SARS - Co V-2 40.0% Analysis AdV hM PV 11.1% 15.0% HEV HRV 14.4% Flu A Flu A-H3 16.7% 12.7% Flu A 12.8% There is a common set of HCoV 9.0% HEV HRV
Slide 28: ADLM guidance on lab diagnosis of respiratory viruses
Molecular market landscape and our strategy ADLM guidance on lab diagnosis of respiratory viruses “The fixed nature of the multiplex PCR panels raises the concern that they might include pathogens that the clinician does not want to test for. Ideally, common pathogens should be tested first followed
Slide 29: FIXED and FLEX approach
Molecular market landscape and our strategy FIXED and FLEX approach Fixed approach - TRADITIONAL Flex approach - NOVEL APPROACH When customers implement diagnostic When all targets are needed every time stewardship initiatives – algorithms Less control over ordering patterns and When customers want
Slide 30: Flex Testing Explained
Molecular market landscape and our strategy Flex Testing Explained 19 target panel Select base targets Select more targets Select more targets 7 TARGETS SELECTED 6 TARGETS SELECTED 6 TARGETS SELECTED Flex credits Flex credits Flex credits Flex credits 100 100 95 90 7 results Buy kits (@base price) +
Slide 31: Flex Testing Explained
Molecular market landscape and our strategy Flex Testing Explained Flex testing is applicable to: Number of targets Type of targets Flexible testing can be leveraged in different ways Selecting high probability targets and reflex to subsequent tiers Pre-determined customized panels based on algorith
Slide 32: Examples of how LIAISON PLEX Respiratory Flex can maximize clinical utility
Molecular market landscape and our strategy Examples of how LIAISON PLEX® Respiratory Flex can be used to maximize clinical utility First-tier winter panel Reflex winter panel Spring / summer panel Persistent cough panel Pre-determined PLEX for Flu A/Flu MDX for PLEX for Rhinovirus/ PLEX for Bordete
Slide 33: Cost optimization
Molecular market landscape and our strategy Cost optimization Simulation based on Clinical Study Data (LIAISON PLEX RSP Flex IFU) Select 7 most prevalent PLEX targets Select additional 6 targets Select additional 6 targets 10% negative 0.5% negative (instant reflex) (instant reflex) 1000 positive pa
Slide 34: Cost optimization
Molecular market landscape and our strategy Cost optimization Simulation based on Clinical Study Data (LIAISON PLEX RSP Flex IFU) Select 7 most prevalent PLEX targets Select additional 6 targets Select additional 6 targets 10% negative 0.5% negative (instant reflex) (instant reflex) 1000 positive On
Slide 35: Impact on reimbursement
Molecular market landscape and our strategy Impact on reimbursement OUTPATIENT INPATIENT Admitted to Not admitted the Hospital to the Hospital Spend at least one Not hospitalized night in the overnight hospital ~50%1 ~50%2 of testing of testing Test is Test is not REIMBURSED reimbursed, but based on
Slide 36: Reimbursement (outpatient)
Molecular market landscape and our strategy Reimbursement (outpatient) VS. VIRUS BACTERIA DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 36
Slide 37: Reimbursement (outpatient)
Molecular market landscape and our strategy Reimbursement (outpatient) Panel coverage limitations: 87631 • 3-5 Respiratory Viral Targets 87631 • $ 142.63 Can be used when targeted testing is not Covered for ~90% of patients appropriate Immunocompromised patients 87632 Viral CPT 87632 • 6-11 Respirat
Slide 38: The value is also beyond respiratory
Molecular market landscape and our strategy The value is also beyond respiratory DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 38
Slide 39: Hospitals are waiting for customizable GI options
Molecular market landscape and our strategy Hospitals are waiting for customizable GI options #targets (viruses/Bacteria) 24 Targets Key differentiative LIAISON PLEX® 11 bacteria value of PLEX 5 viruses Flexible Gastrointestinal Flex Assay (*) 8 parasites • Flexibility and customization • Wide paras
Slide 40: Hospitals are waiting for customizable GI options
Molecular market landscape and our strategy Hospitals are waiting for customizable GI options “ How do we come to consensus on the right number and makeup of panels for specific patient populations. We can’t – so “ please give us the option to customize Presentation by R. Dumm at PASCV (Pan American
Slide 41: Flex testing in GI
Molecular market landscape and our strategy Flex testing in GI Viruses Summer Winter Travel history Children Food exposure DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 41
Slide 42: Flex testing in GI
Molecular market landscape and our strategy Flex testing in GI Bacteria Summer Winter Travel history Children Food exposure DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 42
Slide 43: Flex testing in GI
Molecular market landscape and our strategy Flex testing in GI Parasites Summer Winter Travel history Children Food exposure DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 43
Slide 44: Blood culture
Molecular market landscape and our strategy Blood culture DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 44
Slide 45: Blood Stream Infections
Molecular market landscape and our strategy Blood Stream Infections Blood Positive Gram Pathogen Susceptibilities drawn Blood stain determination Culture (Molecular Test) Gram + Gram Stain to ~60% of cases determine the most appropriate clinical Gram - choice ~30% of cases Yeast ~10% of cases DIASO
Slide 46: Blood Stream Infections
Molecular market landscape and our strategy Blood Stream Infections Blood Positive Gram Pathogen Susceptibilities drawn Blood stain determination Culture (Molecular Test) LIAISON PLEX® Gram + BC Gram+ Assay* ~60% of cases 3 independent panels for the most appropriate clinical Gram - LIAISON PLEX® ch
Slide 47: The right time for the right technology: LIAISON PLEX
Molecular market landscape and our strategy The right time for the right technology: LIAISON PLEX® Operational Efficiency Fiscal Diagnostic Responsibility Stewardship DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 47
Slide 48: PLEX but not only PLEX for stewardship
Molecular market landscape and our strategy PLEX but not only PLEX for stewardship DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 48
Slide 49: The most flexible solution on market
Molecular market landscape and our strategy The most flexible solution on market To achieve the best outcome, diagnostics >10 plex MAGPIX® / MULTIPLEXING CAPABILITIES have to be optimized NxTag LIAISON based on: PLEX® 10 plex • Patient • Season • Setting 1-6 plex And the tests available LIAISON® MDX
Slide 50: LIAISON MDX & LIAISON MDX Plus
Molecular market landscape and our strategy ® LIAISON MDX & ® LIAISON MDX Plus DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 50
Slide 51: LIAISON MDX and MDX Plus: the specialty boxes
Molecular market landscape and our strategy LIAISON® MDX and LIAISON® MDX Plus*: the specialty boxes Sample-to- Open mode answer capabilities Scalable CLIA No need for Differentiated extraction moderate Menu *currently in development. Not available for sales DIASO RIN MO LECULAR DIAG NO ST ICS DAY |
Slide 52: LIAISON MDX assays: targeted specialty menu
Molecular market landscape and our strategy LIAISON® MDX assays: targeted specialty menu Herpes Viruses Respiratory HSV1 & 2 Direct (Swab) Bordetella Direct VZV Swab Direct COVID-19 Direct FDA cleared SARS-CoV-2 Variants Direct (RUO) COVID-19 & Flu A/B Direct Flu A/B & RSV Direct Gen II Group A Stre
Slide 53: Candida auris is an urgent threat
Molecular market landscape and our strategy Candida auris is an urgent threat Emerging multidrug-resistant fungus causing life- threatening health-care associated outbreaks. Rated as an urgent threat by CDC and WHO. To control the rapidly spreading infections caused by C. auris, laboratories must im
Slide 54: Candida auris is an urgent threat
Molecular market landscape and our strategy Candida auris is an urgent threat 2018 10 States 33 Clinical cases Low Medium Urgent DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 54
Slide 55: Candida auris is an urgent threat
Molecular market landscape and our strategy Candida auris is an urgent threat 2020 22 States 757 Clinical cases Low Medium Urgent DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 55
Slide 56: Candida auris is an urgent threat
Molecular market landscape and our strategy Candida auris is an urgent threat 2022 29 States 2377 Clinical cases Low Medium Urgent DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 56
Slide 57: The most flexible solution on the market
Molecular market landscape and our strategy The most flexible solution on the market To achieve the best outcome, diagnostics MAGPIX® / >10 plex MULTIPLEXING CAPABILITIES NxTag have to be optimized LIAISON based on: PLEX® 10 plex • Patient • Season • Setting 1-6 plex And the tests available LIAISON®
Slide 58: LIAISON NES
Molecular market landscape and our strategy ® LIAISON NES DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 58
Slide 59: From sending to a lab...
Molecular market landscape and our strategy From "sending to a lab"…. Urgent Urgent Care Care Hospital Emergency Room Pharmacy Physician office Physician office DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 59
Slide 60: ...to testing onsite
Molecular market landscape and our strategy ...to testing onsite Urgent Urgent Care Care Hospital Emergency Room Pharmacy Physician office Physician office DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 60
Slide 61: Shift of testing by locations
Molecular market landscape and our strategy Shift of testing by locations Trends that emerged from 2015- • Emergency Departments 2019, which then accelerated by • Urgent Care Centers • Specialty Wards (Maternity) the pandemic. Hospital / Lab • Rural / Remote Clinics • Physicians within Network Key r
Slide 62: Increase number of CLIA-waived locations in the US
Molecular market landscape and our strategy Increase number of CLIA-waived locations in the US 340K 310K Pandemic Number of CLIA - waived locations in the US 280K Constant increase of decentralization, 250K with strong acceleration driven 220K by COVID-19, doubling CLIA waived 190K locations in 10 y
Slide 63: Antigen vs. Molecular
Molecular market landscape and our strategy Antigen vs. Molecular 100% 91% 90% 89% Antigen (%) Molecular (%) 90% 85% 82% 80% 80% 78% 75% 72% 69% 70% 65% 62% 60% 58% 55% 52% 50% 48% 45% 42% 40% 38% 35% 31% 30% 28% 24% 21% 20% 17% 14% 10% 10% 5% 2% 3% 0% 2016 2017 2018 2019 2020 2021 2022 2023 2024 20
Slide 64: LIAISON NES: Designed for uncompromised use
Molecular market landscape and our strategy LIAISON® NES: Designed for uncompromised use Develop 50 • WBA Leadership (2) users • Pharmacists (3) • Pharmacists (3) Collect • Pharmacists (3) • Pharmacy Technician (3) • Pharmacy Manager (3) • Nurse (3) Release • Physicians (7) • Technician (2) • Medica
Slide 65: LIAISON NES is designed to fit the Point of Care segment
Molecular market landscape and our strategy LIAISON® NES* is designed to fit the Point of Care segment Notification Disease Made to Error Proof Monitoring Multitask Platform Digital Benefits Benefits Connectivity Rapid Results Plug and Inventory Play Management *currently in development. Not availa
Slide 66: Technology supporting molecular innovation
Technology supporting molecular innovation
Slide 67: Fueling Innovation: Our Molecular Diagnostics R&D Team and Investments
Technology supporting molecular innovation Fueling Innovation: Our Molecular Diagnostics R&D Team and Investments Toronto Milan Madison & Chicago Austin 250 Molecular Diagnostic Researchers working worldwide DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 67
Slide 68: Team Competencies Enable Effective Execution and Support Future Growth
Technology supporting molecular innovation Team Competencies Enable Effective Execution and Support Future Growth PCR (Direct PCR, Quant PCR). Microarrays LAMP Bioinformatics DNA/RNA Extraction EUA Amplification Technologies ddPCR Sequencing Highly Multiplex Assays ASR/RUO Ultrafast Assays CEIVD and
Slide 69: The Technology and Team Enable Diasorin Strategy
Technology supporting molecular innovation The Technology and Team Enable Diasorin Strategy Molecular Diagnostics customers have unique requirements for systems and >10 plex tests depending on MULTIPLEXING CAPABILITIES MAGPIX® / • Indication or Disease Diagnosed NxTag LIAISON • Laboratory Setting/Lo
Slide 70: LIAISON PLEX: Powered by Innovative and Proprietary Technologies
Technology supporting molecular innovation LIAISON PLEX®: Powered by Innovative and Proprietary Technologies Unique Technology Microarray Sample Port Proprietary NanoGrid Ambient Storage technology delivers Eliminates the need for sensitive and highly cold storage with a room specific multiplex temp
Slide 71: LIAISON PLEX: Digital Sample Technology
Technology supporting molecular innovation LIAISON PLEX®: Innovation Demonstrated by Digital Sample Technology The information in the patient sample is digitized DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 71
Slide 72: LIAISON PLEX: Digital Sample Technology
Technology supporting molecular innovation LIAISON PLEX®: Innovation Demonstrated by Digital Sample Technology Digital Sample Base Panel 1st Tier 2nd Tier DIASO RIN MO LECULAR DIAG NO ST ICS DAY | CHICAG O - J ULY, 29 – 2024 | 72
Slide 73: LIAISON PLEX: Demonstrating Track Record
Technology supporting molecular innovation LIAISON PLEX®: Demonstrating Track Record Completed development and obtained 510(k) clearance for LIAISON PLEX® in March 2024 RSP FLEX ASSAY BCY ASSAY Obtained 510(k) clearance in March 2024 Obtained 510(k) clearance in June 2024 First assay clearance set t
Slide 74: LIAISON MDX: Demonstrated Track Record (24 months)
Technology supporting molecular innovation LIAISON MDX: Demonstrated Track Pioneering products addressing Record (24 months) critical clinical needs Simplexa cCMV 510(k) Only cleared product for congenital CMV diagnosis with saliva swab and urine specimen indication Products addressing critical Simp
Slide 75: Commercial execution
Commercial execution
Slide 76: U.S. Hospital Strategy
Commercial execution U.S. Hospital Strategy Strategic initiative • Segmented the market and created teams to address each segment Immunodiagnostic portfolio • Mapped our core assays by Hospital System • Set new strategy of accelerating our sales by decentralizing specialty Molecular testing into key
Slide 77: U.S. Diagnostic sales organization
Commercial execution U.S. Diagnostic sales organization Unique combination of specialists Hospital segment focus with one face to the customer Regional IDN Strategic Accounts (GPO/IDN) Account Exec Hospital Immunodiagnostics Strategy CSLs National Accounts HCSs Commercial Labs Regional IDN Hospital
Slide 78: U.S. Diagnostic sales organization
Commercial execution U.S. Diagnostic sales organization Unique combination of specialists Hospital segment focus with one face to the customer Strategic Accounts (GPO/IDN) Regional IDN Immunodiagnostics Account Exec National Accounts CSLs Hospital Strategy Commercial Labs HCSs Molecular Diagnostics
Slide 79: Diasorin IVD strategy in the U.S. Market
Commercial execution Diasorin IVD strategy in the U.S. Market IVD market in the U.S. Gastrointestinal >10 plex LIAISON ~$ 380M MAGPIX® / PLEX® Post pandemic, the U.S. market looks different than before. NxTag MULTIPLEXING CAPABILITIES Blood Culture 10 plex ~$ 120M The rising cost of healthcare, labo
Slide 80: Diasorin molecular strategy in the U.S. Market
Commercial execution Diasorin molecular strategy in the U.S. Market POINT-OF-CARE TARGETED SOLUTIONS MULTIPLEX SOLUTIONS Expansion in Point-of-Care Menu Expansion & Instrument Enhancement Expansion in Syndromic DECENTRALIZED SETTING DECENTRALIZED/CENTRALIZED LABORATORY SETTING DIASO RIN MO LECULAR D
Slide 81: LIAISON PLEX: Feedback from the first 2 months into the market
Commercial execution LIAISON PLEX®: Feedback from the first 2 months into the market Go-to-market strategy We have mapped the entire syndromic market when it comes to Respiratory, GI, BC, and Meningitis panels in order to target those customers to have relevant conversations Competitive expansion Cu
Slide 82: The right test at the right time
The right test at the right time